XML 12 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 54,017 $ 198,955
Short-term investments 867,063 862,941
Accounts receivable 28,994 38,889
Inventory 15,330 15,292
Other current assets 20,731 21,928
Total current assets 986,135 1,138,005
Long-term investments 34,219 136,662
Property, plant and equipment, net 58,830 59,662
Operating lease right-of-use assets 119,714 126,476
Goodwill 76,501 76,501
Other assets 1,844 1,461
Total assets 1,277,243 1,538,767
Current liabilities:    
Accounts payable 23,660 22,139
Accrued compensation 32,882 14,532
Accrued clinical trial expenses 37,633 44,207
Accrued contract manufacturing expenses 8,088 11,310
Other accrued expenses 19,966 9,676
Operating lease liabilities, current portion 17,740 13,915
Total current liabilities 139,969 115,779
Operating lease liabilities, less current portion 128,718 136,373
Development derivative liability 21,387 0
Liabilities related to the sales of future royalties, net 181,760 200,340
Other long-term liabilities 3,869 8,980
Total liabilities 475,703 461,472
Commitments and contingencies
Stockholders’ equity:    
Preferred stock, $0.0001 par value; 10,000 shares authorized; no shares designated or outstanding at September 30, 2021 or December 31, 2020 0 0
Common stock, $0.0001 par value; 300,000 shares authorized; 184,554 shares and 180,091 shares outstanding at September 30, 2021 and December 31, 2020, respectively 18 18
Capital in excess of par value 3,492,435 3,388,730
Accumulated other comprehensive loss (3,563) (2,295)
Accumulated deficit (2,687,350) (2,309,158)
Total stockholders’ equity 801,540 1,077,295
Total liabilities and stockholders’ equity $ 1,277,243 $ 1,538,767